Short Monolithic Columns - An Enabling Technology for the Purification of Proteins, DNA, and Viruses
M. Peterka, D. Glover, P. Kramberger, M. Banjac, A. Podgornik, M. Barut, A. Štrancar
BioProcessing Journal, March/April 2005
The last 30 years have seen rapid and dramatic developments in recombinant DNA technology and the related biological sciences. In 1972, Paul Berg's group used restriction enzymes to cut DNA in half and then used ligases to stick the pieces of the DNA back together. By doing this, they produced the first recombinant DNA. Within a year, the first genetically engineered bacterium existed. A little more than ten years later, recombinant human insulin was approved for diabetic patients and became the first recombinant healthcare product. Before the end of the 1980s, the first gene therapy trial had occurred. Today, a large number of recombinant proteins are used as marketed drugs and even more are in clinical trials targeting a wide range of diseases.